share_log

Chemomab Therapeutics Q2 EPS $(0.03) Beats $(0.25) Estimate

Benzinga Real-time News ·  Aug 12, 2022 06:04

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.25) by 88 percent. This is a 88.46 percent increase over losses of $(0.26) per share from the same period last year.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment